Gland Pharma

Gland Pharma appointed Deepak Sapra as chief executive officer, subject to his acceptance of the company’s offer, with his tenure due to begin on November 16, 2026. Sapra was serving as chief executive for API and Services at Dr Reddy’s Laboratories and as a board member of Aurigene Pharma Services. He had 27 years of executive experience, including more than 23 years in pharmaceuticals, spanning generics, CDMO services, APIs, licensing and M&A. Gland’s CDMO and B2B businesses each contributed about half of Q1 FY27 revenue, which rose 20% year on year to ₹1,800.3 crore.

Powered by Tijori

Aug 14 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - DEEPAK SAPRA APPOINTED AS CEO EFFECTIVE NOVEMBER 16, 2026

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

Gland Pharma scheduled a one-on-one meeting with UTI MF on August 13 and another with Ashmore on August 20, both arranged by ICICI Securities. It also scheduled one-on-one and group meetings at the Motilal Oswal Investor Conference on August 17. The schedule was subject to change. Gland Pharma reported consolidated FY26 revenue of about ₹6,431 crore, while CDMO and B2B each accounted for roughly half of Q1 FY27 revenue.

Powered by Tijori

Aug 10 (Reuters) - India's Gland Pharma GLAD.NS reported a bigger-than-expected first-quarter profit on Monday, boosted by strong sales in its key European and U.S. markets.

The Hyderabad-based company reported a consolidated net profit of 3.17 billion rupees ($33.3 million) for the quarter ended June 30, from 2.15 billion rupees a year earlier.

That also beat analysts' average estimate of 2.89 billion rupees, per data compiled by LSEG.

Here are some more details:

• U.S. sales, which make up more than half of the total, rose 32%, while the Europe business posted a 20% rise.

• Gland Pharma's results have been consistently boosted since a recovery in production at its Cenexi units in France and Belgium in late 2025.

• Disruption at these units had hurt the drugmaker's results throughout most of last year.

• Overall revenue rose 20% to 18 billion rupees, also beating estimates of 17.33 billion rupees.

• Gland Pharma and several of its Indian generic drugmaker peers that derive a large share of their revenue from the U.S. have been grappling with limited pricing power amid stiff competition in that market.

• Larger rivals Cipla CIPL.NS and Dr Reddy's REDY.NS also reported subdued U.S. sales during the quarter.

($1 = 95.3000 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Ronojoy Mazumdar)

(([email protected]; 8800437922;))

Gland Pharma announced the execution of a strategic manufacturing and supply agreement with an unnamed global pharmaceutical company for technology transfer, manufacture and supply of sterile injectable products in international markets. The agreement covered 55 SKUs across three sites, with annualized revenue potential of about USD 90–100 million once all products were commercialized; revenue was expected to begin in calendar 2029. CDMO operations, including the Cenexi business, accounted for about 46% of group revenue in FY26, while the base CDMO business grew 33%. On August 5, Gland announced a separate partnership with Neuland Laboratories to build a sterile-API suite at its Visakhapatnam site with roughly 1,400 kg a year of microparticle depot capacity.

Powered by Tijori

Gland Pharma received approval from the United States Food and Drug Administration for its generic Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product is a therapeutic equivalent to Merck's Bridion, which recorded US sales of approximately $1.6 billion in the twelve months to April 2026. Gland launched the product on the day of approval through a marketing partner. The company's base injectables business has been expanding, with recent US product launches including Dalbavancin in February 2026 and Liraglutide in August 2025. Gland reported consolidated revenue of ₹64,307 million for the fiscal year ended March 2026.

Powered by Tijori

July 16 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - GETS TAX ORDER OF 35.3 MILLION RUPEES AND PENALTY OF 35.3 MILLION RUPEES

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

** Shares of Gland Pharma GLAD.NS up 12.7% to 2,100 rupees, highest since July 2025

** Drugmaker's March-qtr consol profit nearly doubles to 3.67 billion rupees ($38.12 million); consol rev from ops rises 22.3% to 17.43 billion rupees, supported by launch of new products and increase in capacity

** BofA ("Buy"; PO: 1,868 rupees) says base business margin, excluding profit share, improved sharply aided by higher volumes and new CDMO contracts

** Flags co's FY27 guidance of ~200 million euro revenue was below expectation given the 48-50 million euro run-rate in Q1/Q3FY26 as well as the capacity expansion and new contract wins

** Nomura ("Buy"; PT: 2,390 rupees) says revenue growth was aided by sharp uptick in U.S. revenues, steady Cenexi revenues despite some disruptions in the initial period of the quarter

** Expects potential acceleration in revenue growth in the medium term would support valuation multiples

($1 = 96.2875 Indian rupees)

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

March 4 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - RECEIVES TENTATIVE USFDA APPROVAL FOR BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION

Further company coverage: GLAD.NS

(([email protected];))

March 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• CEO SHYAMAKANT GIRI RESIGNS EFFECTIVE APRIL 30, 2026

Source text: ID:nNSE4Syfgf

Further company coverage: GLAD.NS

(([email protected];))

** India's Gland Pharma GLAD.NS climbs 8.8% to 1,837.30 rupees, its highest since Nov 14

** Drugmaker reports 28% jump in Q3 profit, supported by strong sales in the key European and U.S. markets

** Q3 Rev from ops rises 22.5% to 16.95 billion Indian rupees ($10.86 million)

** Stock top gainer on pharma index .NIPHARM, which is down 0.3%

** Nomura upgrades stock to "Buy" from "Neutral"; says risk‑reward now appears favorable given recent earnings revisions and the stock’s correction

** Gland is taking the right steps to improve visibility for future growth and expects base business to grow in double‑digits in FY27 and earnings to normalize in FY28E

** Avg rating on GLAD at "Hold"; median PT is 2,054.50 rupees - data compiled by LSEG

($1 = 92.0570 Indian rupees)

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Jan 28 (Reuters) - Gland Pharma Ltd GLAD.NS:

• Q3 CONSOL NET PROFIT 2.61 BILLION RUPEES; IBES EST. 2.44 BILLION RUPEES

• Q3 CONSOL REVENUE FROM OPERATIONS 16.95 BILLION RUPEES; IBES EST. 15.87 BILLION RUPEES

Further company coverage: GLAD.NS

(([email protected];))

** Shares of Gland Pharma GLAD.NS rise as much as 4.8% 1,790.4 rupees
** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%
** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis
** Stock last up 1.7%; top pct gainer on the Nifty Pharma index .NIPHARM, which is down 0.6%
** More than 419,000 shares traded, 3.8x the 30-day moving avg
** Mean rating of stock is "hold"; their median PT is 2,050 rupees - data compiled by LSEG
** GLAD fell 3.2% in 2025

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Jan 7 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES USFDA APPROVAL FOR OLOPATADINE SOLUTION

Source text: ID:nNSE86yNM6

Further company coverage: GLAD.NS

(([email protected];))

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2.6% on Friday after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1.

All 20 constituents of the index were lower as of 9:30 a.m. IST. Heavyweight Sun Pharmaceutical Industries SUN.NS fell 3.4%.

The U.S. takes slightly more than a third of India’s drug exports, mostly cheaper generics, which rose 20% to about $10.5 billion in fiscal 2025.

The near term impact of the tariffs is likely to be limited, as India mainly exports generics, ICICI Securities research analyst Pankaj Pandey said in a note.

"That being said, uncertainty still remains whether complex generics and biosimilars will come under tariff embargo in the future," Pandey added.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee)

(([email protected];))

Aug 12 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES APPROVAL FROM USFDA FOR NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION

Further company coverage: GLAD.NS

(([email protected];;))

- Source link: (https://shorturl.at/7l96S)

- Note: Reuters has not verified this story and does not vouch for its accuracy

(Bengaluru newsroom)

(([email protected]; +91 80 6749 1310;))

July 11 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES GMP COMPLIANCE CERTIFICATE FROM DANISH AGENCY

• PASHAMYLARAM FACILITY RECEIVES GMP COMPLIANCE FROM DANISH MEDICINES AGENCY

Source text: ID:nNSE1q7sTy

Further company coverage: GLAD.NS

(([email protected];;))

June 4 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES APPROVAL FOR ANGIOTENSIN II ACETATE INJECTION

• RECEIVES APPROVAL FROM USFDA FOR ANGIOTENSIN II ACETATE INJECTION 2.5 MG/ML

Source text: ID:nnAZN3XNNVV

Further company coverage: GLAD.NS

(([email protected];;))

** Indian pharma companies .NIPHARM climb 1.7%, the most among 13 major sectors

** Nineteen of 20 stocks on index trading higher, with Gland Pharma GLAD.NS leading gains with 4% jump

** U.S. Department of Health and Human Services (HHS) says it expects every drugmaker to align U.S. prices for branded drugs, without generic or biosimilar competition, with the lowest prices in peer countries

** "The HHS order provides relief to generic drugmakers as it talks about price cuts only for branded drugs, indicating that generics will most likely not be affected," Shrikant Akolkar, analyst at Nuvama, says

** Mehul Shah, analyst at HDFC Securities, says order "big relief" especially for biosimilars and generic drug makers

** Cipla CIPL.NS, Dr Reddy's REDY.NS, Sun Pharma SUN.NS up ~2% each; Biocon BION.NS adds 1.6%

** Pharma stocks fell 2% on May 12 after Donald Trump signed order to cut prescription drug prices

(Reporting by Kashish Tandon and Vivek Kumar M in Bengaluru)

(([email protected]))

** Pharmaceutical stocks slide 1.8% after U.S. President Donald Trump signals "major" tariff on pharma imports soon

** Nifty Pharma .NIPHARM index down 6.3% since April 4 when Trump first threatened the duties, ending the sector's brief reprieve

** According to Trump, the pharma duty will incentivise drug cos to move operations to the U.S.

** NIPHARM's all 20 constituents in the red; Gland Pharma GLAD.NS, Dr Reddy's Laboratories REDY.NS, Lupin LUPN.NS, IPCA Laboratories IPCA.NS lose between 2%-4.3%

** Sub-index extends YTD losses to 14.4% vs Nifty 50's .NSEI 5.1% fall

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

April 3 (Reuters) - Shares of Indian drugmakers surged 4% on Thursday, in contrast to the drop in the broader stock market, after U.S. President Donald Trump's administration exempted pharmaceutical products from the list of imports hit by reciprocal tariffs.

The pharma sub-index .NIPHARM was the only one among the 13 major sectors that was trading higher. The benchmark Nifty 50 .NSEI was down 0.74%.

Trump imposed a 26% reciprocal tariff on Indian imports as part of his wider plan to impose a 10% baseline tariff on all imports from April 5, but the duties do not apply to certain goods, including pharmaceuticals.

The U.S. imports nearly a third of Indian pharma products sold overseas. India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.

On the day, Dr Reddy's REDY.NS climbed 6% and was the top gainer on the benchmark Nifty 50 index. Gland Pharma GLAD.NS surged 12% and was the top gainer among pharma stocks.

Cipla CIPL.NS and Sun Pharma SUN.NS rose 4% each.

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Gland Pharma GLAD.NS rises 2.4% to 1,622.85 rupees

** Global investor Vanguard's two funds buy ~1.9 mln shares, aggregating to 1.13% stake in the drug maker at 1,588.69 rupees, NSE data shows

** GLAD top gainer on pharma index .NIPHARM, which is trading flat

** Stock down 9% YTD vs NIPHARM's 7.7% decline

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Indian equities set for inflows of up to $1.4 billion on Friday as FTSE March semi-annual rebalancing to come into effect, per analysts

** ICICI Bank ICBK.NS will be the biggest beneficiary, to see inflows worth $426.9 million from weight increases by FTSE, MSCI and BSE, says IIFL

** Large inflows in ICBK due to merger between bank and ICICI Securities ICCI.NS, whose shares will trade for the last time on Friday

** ICCI shareholders to get 67 ICBK shares per 100 shares of ICCI

** Kotak Mahindra Bank KTKM.NS to see $146 million inflows as FTSE increases weight, says Nuvama

** FTSE adds 360 ONE WAM ONEW.NS, Bajaj Housing Finance BAJO.NS, BSE BSEL.NS and other stocks to FTSE All World Index

** Stocks that might see inflows due to FTSE rebalancing include Zomato ZOMT.NS, ITC Hotels ITCT.NS, Gland Pharma GLAD.NS and BAJO

(Reporting by Vivek Kumar M)

(([email protected];))

Feb 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - CONCLUSION OF US FDA INSPECTION AT COMPANY’S JNPC FACILITY, VISAKHAPATNAM

• GLAND PHARMA - INSPECTION WAS CONCLUDED WITH THREE FORM 483 OBSERVATIONS

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Shares of Gland Pharma GLAD.NS fall ~3.3% to 1462.8 rupees

** Co's Q3 revenue falls 10.4% on production setbacks at French unit Cenexi's site near Paris

** Cenexi sales down due to regulatory inspections, breakeven now pushed back by a year vs Q3 target

** Jefferies says Cenexi "continued to bleed" and India and US saw the biggest sales disappointment in Q3

** InCred Equities cuts to 'sell' from 'hold' on "repeated delays in Cenexi's turnaround"

** Citi retains 'sell' on GLAD's inablity to optimize its 'world class' injectables manufacturing set-up

** 10 analysts avg rating is 'hold', avg PT is 1671 rupees, implying ~13.5% upside to current price -LSEG data

** Including session's decline, stock down 27% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• Q3 CONSOL NET PROFIT 2.05 BILLION RUPEES; IBES EST. 2.04 BILLION RUPEES

• Q3 CONSOL REVENUE FROM OPERATIONS 13.84 BILLION RUPEES; IBES EST. 15.69 BILLION RUPEES

Further company coverage: GLAD.NS

(([email protected];))

Jan 16 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVED ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR DUNDIGAL FACILITY

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

Jan 15 (Reuters) - Gland Pharma Ltd GLAD.NS:

• SHYAMAKANT GIRI WILL ASSUME THE OFFICE OF CHIEF EXECUTIVE OFFICER

Further company coverage: GLAD.NS

(([email protected];;))

Dec 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - ANSM INSPECTION AT CENEXI'S FONTENAY MANUFACTURING FACILITY

• GLAND PHARMA LTD - CENEXI'S FONTENAY FACILITY RECEIVES 10 OBSERVATIONS FROM ANSM

Source text: ID:nBSEbCwXW2

Further company coverage: GLAD.NS

(([email protected];))